Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

LENZ

LENZ Therapeutics Inc

Oct 31 • 04:00PM ET

26.96

Dollar change -0.68
Percentage change -2.46	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BMY GILD REGN VRTX BIIB NBIX ALNY BMRN IONS

| Held by: VTI IWM VXF IWN SCHA VTWO IWC AVSC SCHB VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-9.44	Insider Own	18.39%	Shs Outstand	27.50M	Perf Week	7.75%
Market Cap	741.31M	Forward P/E	-	EPS next Y	-2.70	Insider Trans	0.69%	Shs Float	22.44M	Perf Month	17.78%
Income	-72.31M	PEG	-	EPS next Q	-0.46	Inst Own	71.68%	Short Float	8.96%	Perf Quarter	12.24%
Sales	0.00M	P/S	-	EPS this Y	63.51%	Inst Trans	73.98%	Short Ratio	12.72	Perf Half Y	64.29%
Book/sh	7.46	P/B	3.61	EPS next Y	9.62%	ROA	-29.53%	Short Interest	2.01M	Perf Year	128.78%
Cash/sh	7.14	P/C	3.78	EPS next 5Y	33.00%	ROE	-34.67%	52W Range	9.51 - 31.00	Perf YTD	117.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-483.52%	ROI	-37.28%	52W High	-13.03%	Beta	0.49
Dividend TTM	-	Quick Ratio	23.23	Sales past 5Y	0.00%	Gross Margin	-	52W Low	183.40%	ATR (14)	1.90
Dividend Ex-Date	Mar 15, 2024	Current Ratio	23.23	EPS Y/Y TTM	41.13%	Oper. Margin	0.00%	RSI (14)	55.86	Volatility	6.87% 8.09%
Employees	6	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	35.57
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	94.13%	Payout	-	Rel Volume	0.97	Prev Close	27.64
Sales Surprise	-	EPS Surprise	16.44%	Sales Q/Q	-	Earnings	Nov 06 BMO	Avg Volume	157.94K	Price	26.96
SMA20	3.55%	SMA50	12.81%	SMA200	39.88%	Trades		Volume	153,382	Change	-2.46%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-27-24	Initiated	Raymond James	Outperform	$37
Aug-12-24	Initiated	H.C. Wainwright	Buy	$38
Apr-15-24	Initiated	William Blair	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform	$32
Apr-10-24	Initiated	Citigroup	Buy	$34
Mar-27-24	Initiated	Piper Sandler	Overweight	$28
Feb-23-23	Downgrade	Cowen	Outperform → Market Perform
Feb-23-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$3
Feb-23-23	Downgrade	BofA Securities	Neutral → Underperform	$3 → $2
Jan-25-23	Downgrade	BTIG Research	Buy → Neutral
Jan-18-23	Downgrade	BofA Securities	Buy → Neutral	$7 → $3
Jan-06-23	Downgrade	SVB Leerink	Outperform → Mkt Perform	$11 → $2
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$14 → $7
Sep-15-22	Initiated	Cantor Fitzgerald	Overweight	$12
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$12
Apr-14-22	Initiated	BTIG Research	Buy	$18
Mar-22-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19 → $8
Feb-18-22	Initiated	RBC Capital Mkts	Sector Perform	$11
Jul-20-21	Initiated	SVB Leerink	Outperform	$34
Jul-20-21	Initiated	Morgan Stanley	Overweight	$35

Show Previous Ratings

Oct-30-24 08:00AM	LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 (GlobeNewswire)
Oct-27-24 09:00PM	CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 (GlobeNewswire)
Oct-22-24 08:10AM	Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 (TipRanks) -9.27%
Oct-21-24 08:00AM	LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia (GlobeNewswire)
Sep-30-24 08:00AM	LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences (GlobeNewswire)
04:01PM	Loading…
Aug-27-24 04:01PM	LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	LENZ Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia (GlobeNewswire)
Aug-07-24 04:01PM	LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 (GlobeNewswire)
Jul-15-24 08:00AM	LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital (GlobeNewswire)
Jun-10-24 08:00AM	LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024 (GlobeNewswire) +14.18%
May-30-24 08:00AM	LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-24 09:03AM	LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:01PM	LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-01-24 04:01PM	LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024 (GlobeNewswire)
07:00AM	Loading…
Apr-03-24 07:00AM	LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials (Business Wire)
Apr-02-24 04:01PM	LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials (Business Wire)
Mar-21-24 04:30PM	LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress (Business Wire) +7.64%
10:09AM	11 Stocks that Paid Special Dividends in 2024 (Insider Monkey)
Mar-08-24 05:00PM	Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics (Business Wire) +18.79%
Mar-01-24 10:48AM	Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Feb-02-24 11:58AM	Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:07PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FNCB, PWFL, DOC, GRPH (GlobeNewswire)
Nov-16-23 12:00PM	What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock (Zacks)
Nov-15-23 07:00AM	LENZ Therapeutics and Graphite Bio Announce Merger Agreement (Business Wire)
Jun-23-23 07:00AM	Graphite Bio Announces Departure of Chief Financial Officer (Business Wire)
May-15-23 07:44AM	Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22% (Simply Wall St.) +6.02%
May-10-23 10:18AM	Should You Buy Graphite Bio (GRPH) Ahead of Earnings? (Zacks)
Apr-26-23 02:10PM	12 Gene Editing Stocks With the Best Long-Term Potential (Insider Monkey)
Mar-29-23 04:20PM	11 Most Promising Gene Editing Stocks According to Analysts (Insider Monkey)
10:12AM	Loading…
Mar-25-23 10:12AM	We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate (Simply Wall St.)
Mar-20-23 04:05PM	Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results (Business Wire)
Feb-23-23 05:36PM	Sickle-cell gene therapy developer stops program, cuts half of staff (American City Business Journals) +15.91%
Feb-22-23 04:05PM	Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring (Business Wire)
Jan-10-23 09:35AM	Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround (Zacks)
Jan-06-23 05:54PM	Two Covid-era biotech IPOs Spruce and Graphite Bio see stock head in different directions (American City Business Journals) -39.54%
09:07AM	Graphite Bio Shares Tank After Pausing Sickle Cell Therapy Study (Benzinga)
Jan-05-23 05:57PM	Graphite Bio pauses early-stage blood disease therapy trial (Reuters)
04:05PM	Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease (Business Wire)
Dec-11-22 10:00AM	Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting (Business Wire)
Nov-21-22 08:00AM	Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-17-22 09:45AM	2 Strong Buy Penny Stocks That Could See 200% Gains (Or More) (TipRanks)
Nov-09-22 04:05PM	Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results (Business Wire)
Nov-03-22 09:05AM	Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition (Business Wire)
Oct-16-22 08:33AM	Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation (Simply Wall St.)
Oct-11-22 08:00AM	Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention (Business Wire)
Sep-06-22 08:00AM	Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire)
Aug-30-22 05:47PM	Potential sickle cell disease 'cure' jumps to clinic, yet investors remain cool (American City Business Journals)
Aug-11-22 04:05PM	Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results (Business Wire) +5.03%
08:16AM	Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease (Business Wire)
Jun-17-22 02:26PM	BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock (Benzinga) +12.15%
Jun-01-22 08:00AM	Graphite Bio Announces Participation in Jefferies Healthcare Conference (Business Wire)
May-29-22 02:15PM	I'm 'Following Up' on a Biotech Trade With Attractive Potential (TheStreet.com)
May-16-22 06:00AM	Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting (Business Wire)
May-12-22 04:05PM	Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results (Business Wire) +14.04%
May-09-22 08:13AM	Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) -19.44%
May-04-22 08:00AM	Graphite Bio Announces Participation in Upcoming Investor Conferences (Business Wire) +6.22%
May-03-22 08:00AM	Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease (Business Wire)
May-02-22 04:38PM	Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program (Business Wire)
Mar-28-22 08:00AM	Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference (Business Wire)
Mar-23-22 12:28PM	Insiders who purchased Graphite Bio, Inc. (NASDAQ:GRPH) earlier this year lose an additional US$64k as the stock sinks to US$6.16 (Simply Wall St.) -8.60%
08:00AM	Graphite Bio Announces Formation of Scientific Advisory Board (Business Wire)
Mar-21-22 08:25AM	Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results (Business Wire) -15.15%
Mar-03-22 08:00AM	Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference (Business Wire)
Mar-02-22 08:00AM	Graphite Bio Appoints Alethia Young as Chief Financial Officer (Business Wire)
Feb-08-22 10:20AM	Is a Surprise Coming for Graphite Bio (GRPH) This Earnings Season? (Zacks)
Jan-27-22 08:00AM	Graphite Bio Announces Participation in Upcoming Investor Conferences (Business Wire) -6.67%
Jan-26-22 06:30PM	Expanding gene editing firm Graphite Bio signs new lease in South San Francisco (American City Business Journals)
Dec-11-21 09:00AM	Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition (Business Wire)
Dec-07-21 08:00AM	Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease (Business Wire) +5.94%
Nov-17-21 08:00AM	Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease (Business Wire)
Nov-10-21 04:05PM	Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results (Business Wire)
Nov-04-21 09:13AM	Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition (Business Wire)
Oct-21-21 08:00AM	Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit (Business Wire)
Oct-18-21 11:00AM	10% Owner Of Graphite Bio Makes $670K Buy (Benzinga)
04:37AM	3 Stocks Insiders Are Buying (Benzinga)
Oct-12-21 01:00PM	Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention (Business Wire)
Oct-05-21 08:00AM	Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention (Business Wire) -6.79%
Sep-25-21 10:12AM	We Think Graphite Bio (NASDAQ:GRPH) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-30-21 08:00AM	Graphite Bio Announces Participation in Upcoming September Investor Conferences (Business Wire)
Aug-12-21 04:05PM	Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results (Business Wire)
Jun-30-21 05:15PM	Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) +11.34% -8.07%
Jun-24-21 09:08PM	Graphite Bio Announces Pricing of Upsized Initial Public Offering (Business Wire)

LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Solana Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schimmelpennink Evert B.	President, CEO and Secretary	Jul 22 '24	Option Exercise	1.04	45,000	46,800	45,000	Jul 23 08:16 PM
Chevallard Daniel R.	Chief Financial Officer	May 14 '24	Buy	15.68	3,188	49,988	3,188	May 15 04:13 PM
MCCOLLUM JAMES W	Director	May 13 '24	Buy	15.99	31,332	501,093	525,565	May 14 05:29 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 21 '24	Buy	15.03	998,009	15,000,075	3,319,339	Mar 25 08:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LENZ

LENZ Therapeutics Inc

Upgrade your FINVIZ experience